Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Assets (2021 - 2025)

Indivior Pharmaceuticals has reported Assets over the past 5 years, most recently at $1.2 billion for Q4 2025.

  • Quarterly results put Assets at $1.2 billion for Q4 2025, down 8.74% from a year ago — trailing twelve months through Dec 2025 was $1.2 billion (down 8.74% YoY), and the annual figure for FY2025 was $1.2 billion, down 8.74%.
  • Assets for Q4 2025 was $1.2 billion at Indivior Pharmaceuticals, down from $1.4 billion in the prior quarter.
  • Over the last five years, Assets for INDV hit a ceiling of $1.8 billion in Q4 2021 and a floor of $1.2 billion in Q4 2025.
  • Median Assets over the past 5 years was $1.4 billion (2025), compared with a mean of $1.5 billion.
  • Biggest five-year swings in Assets: dropped 0.62% in 2023 and later dropped 25.14% in 2024.
  • Indivior Pharmaceuticals' Assets stood at $1.8 billion in 2021, then decreased by 3.44% to $1.8 billion in 2022, then fell by 0.62% to $1.8 billion in 2023, then decreased by 25.14% to $1.3 billion in 2024, then decreased by 8.74% to $1.2 billion in 2025.
  • The last three reported values for Assets were $1.2 billion (Q4 2025), $1.4 billion (Q3 2025), and $1.5 billion (Q2 2025) per Business Quant data.